

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 45/05, 38/00, 38/19, C07K 1/00, 14/52		A1	(11) International Publication Number: <b>WO 97/35620</b> (43) International Publication Date: 2 October 1997 (02.10.97)
<p>(21) International Application Number: <b>PCT/US97/04914</b></p> <p>(22) International Filing Date: 24 March 1997 (24.03.97)</p> <p>(30) Priority Data: 60/014,177 26 March 1996 (26.03.96) US 60/014,951 5 April 1996 (05.04.96) US</p> <p>(71) Applicant (for all designated States except US): <b>ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).</b></p> <p>(72) Inventors; and</p> <p>(73) Inventors/Applicants (for US only): <b>BEALS, John, M. [US/US]; 6710 Bluffridge Parkway, Indianapolis, IN 46278-1853 (US). EDWARDS, Mary, J. [US/US]; 340 East 38th Street #309, Indianapolis, IN 46205 (US). PIKAL, Michael, J. [US/US]; 14 Turnpike Road, Ashford, CT 06278 (US). RINELLA, Joseph, V., Jr. [US/US]; 3640 Roman Drive, Brownsburg, IN 46112 (US).</b></p> <p>(74) Agent: <b>CALTRIDER, Steven, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</b></p>		<p>(81) Designated States: <b>AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b> With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: <b>FORMULATIONS OF OB PROTEIN</b></p> <p>(57) Abstract</p> <p>The present invention provides lyophilized compositions of an obesity protein. The compositions demonstrate remarkable stability and ease of manufacture and, significantly, are useful to prepare stable pharmaceutical formulations useful for treating patients in need thereof. Thus, the invention further provides methods of using such formulations for the treatment of obesity and disorders associated with obesity such as diabetes, cardiovascular disease and cancer.</p>			
<p><b>BEST AVAILABLE COPY</b></p>			